海洋细菌可用于治疗葡萄球菌感染

Aggressive infections are a growing health problem all over the world. The development of resistant¹ bacteria is rampant²（猖獗的） and, in the United States, resistant staphylococci（葡萄状球菌） cause more deaths than AIDS on an annual basis. Researchers from the University of Copenhagen are studying a new form of treatment based on marine³ bacteria. The results have been published in PLOS ONE. Staphylococci have been a big problem for hospitals all over the world since the 1940s and, for many years, the pharmaceutical⁴ industry has been able to develop new antibiotics⁵ to keep up with the emergence⁶ of the aggressive bacteria. However, from 1970 to 2000, virtually no new antibiotics have come on the market. Staphylococci are gaining in the race -- resistance is growing, and treatment options are few. In short, doctors have been set back to the time before penicillin⁷ was mass produced.

 

Research performed in collaboration⁸ between the University of Copenhagen and the Technical University of Denmark (DTU) focus on a new form of treatment -- so-called antivirulence therapy -- based on marine bacteria producing Staphylococcus inhibiting¹⁰ compounds.

 

"The marine compounds effectively inhibit⁹ the ability of staphylococci to form toxins¹² and camouflage¹³（伪装，掩饰） proteins that prevent our immune system from reacting to an infection. At the same time, marine compounds appear to paralyse a sophisticated communication system that provides staphylococci the opportunity to undertake a coordinated¹⁴ attack on the organism," says Anita Nielsen, PhD. She has published new results in PLOS ONE with Professor Hanne Ingmer from the Department for Veterinary Disease Biology at the University of Copenhagen's Faculty¹⁵ of Health and Medical Sciences.

 

In the United States, resistant staphylococci cause more deaths than AIDS on an annual basis. Antivirulence therapy protects the body's natural bacterial¹⁶ flora¹⁷ and disarms¹⁸, so to speak, infectious staphylococci bacteria. In this way, the body's immune system potentially gets a chance to defend itself against infection -- and, in the long term, this form of treatment can mean that patients experience fewer harmful side effects.

 

Potent¹⁹ compound from the Solomon Islands

 

The researchers have analyzed²¹ compounds extracted from marine bacteria collected from all over the world on the Galathea 3 expedition, which took place from August 2006 until April 2007. One particular compound, Solonamid B, isolated²² from a marine bacterium²³ found near the Solomon Islands, is of particular interest.

 

"Solonamid B inhibits²⁴ the ability of staphylococci to produce various toxins that break down our blood cells. White blood cells in particular are important in this context, because they participate in the fight against invasive bacteria during an infection. When Solonamid B is added to bacteria, it reduces their toxin¹¹ production so only a fifth of the white blood cells die that would otherwise succumb²⁵ to the staphylococci toxins," says Professor Hanne Ingmer.

 

It has required demanding laboratory work to analyze²⁰ the compounds that can form the basis for antivirulence therapy in the future. Purification and identification of the Solonamid B used for the cell studies were undertaken in collaboration with DTU. Researchers at DTU extracted the compounds that researchers at University of Copenhagen subsequently tested biologically. Future experiments will show whether the antivirulence compounds also work in animals and human beings.

分享到：